A B S T R A C T

Background
Strong evidence supports the use of metered-dose inhalers combined with a spacer for delivering rapid-acting inhaled beta-2 agonists in the treatment of acute exacerbations of asthma in children. The high cost and lack of availability of commercially produced spacers however, have limited their use in developing countries.
Objectives
The aim of this review was to compare the response to inhaled beta-2 agonists delivered through metered-dose inhaler using homemade spacers, to the use of commercially produced spacers, in children with acute exacerbations of wheezing or asthma.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) The Cochrane Library Issue 3, 2007,(up to August 2007) MEDLINE , EMBASE, CINHAL, LILACS and reference lists of included studies. We contacted authors and known experts in the field, and approached pharmaceutical companies that manufacture inhalation spacers to identify additional published or unpublished data. No language restrictions were applied.
Selection criteria
Trials comparing treatment with rapid acting beta 2-agonists delivered though MDI attached to home-made spacers, with the same bronchodilator therapy delivered with MDI and commercially produced spacers, in children under 18 years with acute exacerbations of wheezing or asthma.
Data collection and analysis
Two review authors independently extracted the data and assessed trial quality. Missing data were obtained from the authors or estimated from information available in published reports.
Main results
Six trials with 658 participants met the inclusion criteria . At the time of this report, five trials were published in full text, and one study was available in abstract form only. No significant differences were demonstrated between the two delivery methods in terms of need for hospital admission (RR 1.00, 95% CI 0.63 to 1.59), change in oxygen saturation (SMD -0.03, 95% CI -0.39 to 0.33), PEFR (SMD 0.04, 95% CI -0.72 to 0.80), clinical score (WMD 0.00, 95% CI -0.37 to 0.37), in terms of need for additional treatment (RR 1.18, 95% CI 0.84 to 1.65), or regarding change in heart rate per minute (SMD 0.09, 95% CI -0.24 to 0.42).
Authors' conclusions
Overall, this review supports did not identify a difference between these two methods for delivering bronchodilator therapy to children with acute asthma or lower airways obstruction attacks. Care should be taken in the interpretation and applicability of our results because of the small number of RCTs along with few events available meeting the criteria for inclusion in the review, absence of the primary outcome of interest and other clinically important outcomes in the majority of included studies. The possible need for a facemask in younger children using home-made spacers should also be considered in practice.
P L A I N L A N G U A G E S U M M A R Y
Commercial versus home-made spacers in delivering bronchodilator therapy for acute therapy in children
The aim of this review was to compare the response to inhaled beta-2 agonists delivered through metered-dose inhaler (MDI) attached to home-made spacers, to beta-2 agonists delivered through MDI attached to commercially produced spacers, in children with acute exacerbations of wheezing or asthma. Six randomized clinical trials (RCT) with 658 participants met the inclusion criteria of the review. Overall, this review fails to identify a difference between these two delivery methods for delivering bronchodilator therapy to children with acute asthma or lower airways obstruction attacks; however, given the small total sample and wide confidence intervals, equivalence between the treatments cannot be claimed. Effective use of MDI requires synchronization of inhalation with actuation of the device. Since synchronization is difficult in children, spacer devices are used to overcome this poor co-ordination problem. Spacers have further advantages in that they improve efficacy (increase lung deposition and decrease oropharyngeal deposition) and reduce side effects from inhaled drugs (Amirav 1997; Singhal 2001). For this reason, inhaled therapy using an MDI with attached spacer has been increasingly recognized as the optimal method for delivering rapid acting beta 2-agonists for acute exacerbations of wheezing or asthma. A wide variety of commercially produced spacers are available; these differ in shape, size, material out of which they are constructed, and the presence of valves (Zar 2002a). The high cost and lack of availability of commercial produced spacers have limited their use in developing countries (Zar 2002a).
B A C K G R O U N D
As an alternative, rapid acting beta 2-agonists via MDI have been delivered attached to home-made spacers for treating children with acute exacerbations of wheezing or asthma (Zar 1999; Singhal 2001; Zar 2002a). A wide variety of home-made spacers have been developed, including plastic cold-drink bottles, plastic mineral water bottles, polystyrene cups, plastic zip-up bags, and paper spacers. In spite of the wide use of these home-made spacers in developing countries, there are only a few studies comparing their use for delivery of rapid acting beta 2-agonists via MDI versus the same bronchodilator therapy with commercially produced spacers for treating acute exacerbations of wheezing or asthma in children under 18 years of age.
Although several studies have concluded that rapid acting beta 2-agonists via MDI given attached to home-made spacers produce similar bronchodilation to the same bronchodilator therapy delivered with commercially produced spacers for treating acute exacerbations of wheezing or asthma in children (Panicker 2001; Singhal 2001; Quetulio 2002; Obgaidze 2005), some of these studies were not powered sufficiently to detect differences between the two devices. We therefore aimed to review the literature to determine if the existing evidence allows concluding that the bronchodilatory response to beta 2-agonists, delivered through metered-dose inhaler (MDI) attached to home-made spacers, is equivalent to the bronchodilatory response to beta 2-agonists delivered through MDI attached to commercially produced spacers, in children with acute exacerbations of wheezing or asthma.
O B J E C T I V E S
The aim of this review was to compare the response to inhaled beta-2 agonists delivered through metered-dose inhaler (MDI) attached to home-made spacers, to beta-2 agonists delivered through MDI attached to commercially produced spacers, in children with acute exacerbations of wheezing or asthma.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomised clinical trials (RCT) including open and blinded study designs.
Types of participants
Children under 18 years with acute exacerbations of wheezing or asthma presenting to an ED or equivalent care setting.
Types of intervention
Intervention: Rapid acting beta 2-agonists via MDI given attached to home-made spacers. Combination treatment with anti-cholinergic agents was permitted. Controls: The same bronchodilator therapy delivered with commercially produced spacers. Combination treatment with anti-cholinergic agents was permitted.
Types of outcome measures
The primary outcome measure was the need for hospital admission. Secondary outcomes measures were changes from baseline in peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV 1 ), oxygen saturation (SaO 2 ), respiratory rate (RR), clinical scores, and physical signs, such as dyspnea, accessory muscle use, and wheezing. Other secondary outcomes measures were intensive care unit (ICU) admission rates, emergency department length of stay, need for additional treatment upon completion of the intervention protocol, and adverse effects such as heart rate (HR), dysrhythmia, tremor, and nausea.
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Airways Group methods used in reviews. (spacer* or MDI or bronchodilat* or nebuli* or vapori* or aerosol* or inhal* or "holding chamber" or holding-chamber) and (bottle* or home-made* or "home made" or homemade or alternative* or improvi* or cup or plastic or paper or polystyrene)
We included citations in any language. We also reviewed the bibliographies of the randomized trials identified, contacted the authors of included trials and known experts in the field, and approached pharmaceutical companies that manufacture inhalation spacers to identify additional published or unpublished data.
M E T H O D S O F T H E R E V I E W
I. Trial selection
Two review authors (CRM, MPS) scanned the abstracts and titles of articles retrieved by the electronic and handsearches for eligibility, according to the inclusion criteria above. One of the review authors retrieved full copies of all those deemed potentially eligible for closer examination. Two review authors determined whether or not they met eligibility criteria; if necessary we sought advice from other authors. Disagreement was resolved by consensus.
II. Data extraction and management
We developed our data abstraction forms a priori to capture specific items of data needed for this review. We pilot-tested the data extraction form with a sample of three included studies to ensure clarity, completeness and ease of use. We extracted data on study design, details on participants (including age, gender, number in each group), description of the interventions (including process), and description of outcomes, including timing of assessment, and adverse effects. Two review authors (CRM, MPS) independently extracted data from trials to the specially designed form, one review author (CRM) then entered into RevMan 4.2.8, and this was checked by a second using the double data entry facility. If data were not reported in abstractable form, we contacted one of the authors of the included study for additional information. For binary outcome measures we calculated a pooled estimate of the relative risk (RR) of the treatment effect for each outcome. For continuous outcomes, we recorded either mean change from baseline for each group or mean values after intervention, and their respective standard deviations or standard errors, and calculated mean differences. If standard deviations or standard errors were missing, we tried to extract them from other relevant information reported in the paper (P-values, confidence intervals, etc). If the authors could not be contacted or if the information was no longer available, this was reported.
III. Trial quality assessment
Two review authors (CRM, MPS) independently assessed the methodological quality using two methods. Firstly, all included trials were scored using the Cochrane approach to assessment of allocation concealment, using the following principles (Schulz 1995): Grade A: Adequate concealment Grade B: Uncertain Grade C: Clearly inadequate concealment Secondly, the methodological quality of the eligible RCTs was also assessed with a modified version of a 5-point scoring instrument, proposed by Jadad (Jadad 1996), and summarized as follows: 1. Was the trial described as randomized (1 = yes; 0 = no)?; 2. Was the trial described as double-blind (1 = yes; 0 = no)?; 3. Was there a description of withdrawals and dropouts (1 = yes; 0 = no)?; 4. Was the method of randomisation well described and appropriate (1 = yes;0 = no); 5. Was the method of blinding well described and appropriate (1 = yes; 0 = no)?; 6. One point was deducted if methods for randomization or blinding were inappropriate.
The modification of the original Jadad scoring instrument consisted of giving one additional point for each of the two items of (1) description and appropriateness of the method of generating the sequence of randomization and (2) description and appropriateness of the method of double blinding, as opposed to the original Jadad scale, which would only award one point even if both items were fulfilled.
Inter-rater reliability was measured by using simple agreement and kappa weighted statistics.
IV. Data analysis
Cochrane Review Manager 4.2.8 software (RevMan 2006) and RevMan Analyses 1.0.2, its companion, were used to compile and analyze the data. For binary outcomes, we calculated relative risks (RR) and their 95% confidence intervals (CI) for each study. For continuous outcomes, we calculated the weighted mean difference (WMD) (for variables measured using the same scale), or the standardised mean differences (SMD) (for variables measured using different scales) and 95% CI. We measured heterogeneity among trials using I 2 statistic (Higgins 2002), heterogeneity test Q and by comparing the fixed-effect model (where only withinstudy variation is considered to influence the uncertainty of the weighted mean results) and random-effects model results (in which both within-study and between-study variations are included in the assessment of the uncertainty of the overall mean results). If statistical heterogeneity was not found, a fixed-effect model was used with 95% confidence interval (CI). If significant heterogeneity was detected, we devoted further research to identify possible causes of heterogeneity for the following characteristics: methodological quality of included studies, severity of asthma attack at presentation, age, presence of valves in commercially produced spacers, material of home-made spacer, and dose of bronchodilator. We explored the impact of these characteristics on heterogeneity and the effectiveness of the intervention by means of subgroup analyses.
In the sensitivity analysis we evaluated the impact of the study quality by separating studies according to low risk of bias (characteristic = "adequate") or medium/high risk of bias (characteristic = "unclear/inadequate") for allocation concealment. We also performed sensitivity analysis with respect to the modified version of the Jadad scale.
D E S C R I P T I O N O F S T U D I E S
The computerised search yielded 1531 citations. A total of 31 studies were examined in full text for possible inclusion. One paper was translated from Russian into English. This left six trials and data for 658 children and adolescents available for meta-analysis. A total of 25 studies were excluded due to the following reasons Hospitalization rate was used in only one study (Zar 2007) , and the reporting of adverse effects was variable. One study included patients with acute lower airway obstruction, without a diagnosis of asthma (Zar 2007). One of the studies included in the review was reported as an abstract and we wrote to one of the authors in an attempt to obtain complete data from the study, but the authors did not respond to requests for further information (Quetulio 2002).
M E T H O D O L O G I C A L Q U A L I T Y
The methodological quality of the included studies was variable (see table 'Characteristics of included studies'). In general the sample size of the majority of studies was small (range 30 to 400 participants). 
R E S U L T S
The primary outcome of hospital admission was available only from one study (Zar 2007) . In this study the proportion of admitted patients was identical in the home-made and commercial spacer groups (15% in each group), so no significant differences were demonstrated between the two spacers in terms of this outcome (RR 1.0, CI 95% 0.63 to 1.59). Two studies (Panicker 2001; Singhal 2001) (120 patients) had complete data on measurements of change in SaO 2 . When comparing home-made spacers and commercial spacers, no significant differences were demonstrated between the two delivery methods in terms of change in SaO 2 (SMD -0.03, 95% CI -0.39 to 0.33). Two additional trials could not be pooled owing to skewness of the data and lack of report of mean and standard deviation for this outcome (Zar 1999; Zar 2007). These studies showed that the median change in SaO 2 was not significantly different between the two spacers (P = 0.52 and P = 0.53, respectively). No significant differences were demonstrated between the two delivery methods in terms of change in clinical score (WMD 0.0, 95% CI -0.37 to 0.37). This finding is based on one study containing 20 participants (Chong Neto 2005). Two additional studies could not be pooled owing to skewness of the data and lack of report of mean and standard deviation for this outcome (Zar 1999; Zar 2007). These studies did not show significant differences in the median number of change in clinical score between home-made and commercial spacer groups (P = 0.60 and P = 0.53, respectively).
Pulmonary function tests
Two studies involving 90 patients reported change in PEFR (Panicker 2001; Quetulio 2002) . No significant differences were demonstrated between the two spacers in terms of this outcome based on a random effects model (SMD 0.04, 95% CI -0.72 to 0.80). These results should be interpreted with caution because significantly heterogeneity (X 2 = 2.99, df =1, I 2 = 66.6%, P = 0.08) was identified among trials. Two additional studies could not be pooled owing to skewness of the data and lack of report of mean and standard deviation for this outcome (Zar 1999; Singhal 2001). These studies did not show significant differences in the median change in PEFR between home-made and commercial spacer groups (P = 0.95 and P = 0.4, respectively).
Clinical outcomes
Three studies involving 552 patients had complete data on the proportion of children who needed additional treatment (Zar 1999; Panicker 2001; Zar 2007). When comparing home-made spacers and commercial spacers, no significant differences were demonstrated between groups in terms of this outcome (RR 1.18, 95% CI 0.84 to 1.65). These results did not change significantly when studies of lower methodological quality or studies that included patients without asthma diagnosis were excluded. Heterogeneity was found among trials pooled for change in PEFR (X 2 = 2.99, df = 1, I 2 = 66.6%, P = 0.08) but not for other outcomes.
Vital signs
There was insufficient information to pool outcomes such as change in RR, in accessory muscle use, in grading of dyspnea, and in breath sounds due to the insufficient number of trials reporting these outcomes. Analysis of the only trial which tested these outcomes did not show significant differences between patients treated with home-made spacers when comparing with patients treated with commercial devices (P > 0.05) (Panicker 2001). One additional trial could not be pooled owing to skewness of the data and lack of report of mean and standard deviation for change in RR. (Singhal 2001) . This study showed a significantly greater decline in RR with the commercial spacer compared with the homemade device (P = 0.003).
No data were available for the following outcome measures in any study: emergency department length of stay, dysrhythmia and ICU admission.
We wrote to five authors of the six included studies for further information and received three replies. Any replies or data received from authors after publication of this review will be incorporated into future updates of the review.
D I S C U S S I O N
This systematic review constitutes an effort to incorporate the best evidence available up to August 2007 on the role of home-made spacers compared to commercial spacers in delivering bronchodilator therapy to children with acute asthma or lower airway obstruction attacks. Overall, this review fails to identify a difference between these two delivery methods for delivering bronchodilator therapy to children with acute asthma or lower airways obstruction attacks. When comparing home-made spacers and commercial spacers, no significant differences were demonstrated between the two delivery methods in terms of hospital admission, change in SaO 2 , clinical score, change in PEFR, and need for additional treatment. Moreover, sensitivity analysis did not show any significant influences of quality of methods in the efficacy of the commercially produced spacers compared to home-made devices in delivering bronchodilator therapy to children with acute exacerbations of wheezing or asthma.
In our meta-analysis we also looked at adverse effects but these were difficult to analyse because there was insufficient information to be pooled. The only one of these measurements that could be pooled was change in HR. When comparing home-made spacers and commercial spacers, no significant differences were demonstrated between groups in terms of this outcome.
These are very relevant findings since acute exacerbations of asthma account for the largest part of direct health costs for asthma in most countries, and the fact that inhaled therapy using a MDI with attached spacer has been increasingly recognized as the optimal method for delivering rapid acting beta 2-agonists for acute exacerbations of wheezing or asthma, and that high cost and lack of availability of commercially produced spacers have limited their use in developing countries.
The following outcome measures did not show any heterogeneity when data from different trials were combined: change in SaO 2 , change in HR, and need for additional treatment. Statistical heterogeneity was found among trials pooled for change in PEFR (X 2 = 2.99, df = 1, I 2 = 66.6%, P = 0.08). The statistical heterogeneity for this outcome is difficult to explain due to the limited number of trials reporting this outcome in a way that could be pooled (only two trials). No significant differences were demonstrated between the two spacers in terms of this outcome based on a random effects model (SMD 0.04, 95% CI -0.72 to 0.80). However, these results should be interpreted with caution because of this statistical heterogeneity among trials, and because there are very few studies, and very few events for this outcome.
Interpretation and applicability of our results needs to be cautious for several reasons: (1) The small number of RCTs along with few events available meeting the criteria for inclusion in the review, (2) absence of the primary outcome of interest (hospital admission, available from only one study) and other clinically important out-comes in the majority of included studies, (3) only limited analysis of outcomes such as change in SaO 2 , change in clinical score, and change in PEFR was possible due to data being presented as medians, and (4) the careful preparation and use of delivery devices in some studies (Zar 2007 used a facemask with the home-made spacer in younger children and took measures to reduce static in both spacers and bottles). Valved commercial spacers contain a one-way, low resistance valve that allows the aerosol to remain within the device until the patient's inhalation effort opens the valve. The theoretical advantages of these valved holding spacers compared to non-valved devices consist in that the former improve coordination with inspiratory flow, and eliminate the cold-Freon effect (Rubin 2005). Moreover, if the child exhales through nonvalved spacers, whether home-made or not, any remaining drug which would have been inhaled on the second inspiration may be lost. However, it's important to take into account that it also has been described advantages of the non-valved spacers over valved holding chambers: the former devices may increase pulmonary aerosol deposition, especially in young children or those with airway obstruction (since overcoming the resistance of the valve on inspiration may be difficult for such patients), and may also minimize the amount of dead space in the spacer (Zar 2002b). A possible weakness of this review is the inaccessibility of data on outcomes known to have been measured (but unreported), and data not presented in a form that can be combined in the metaanalysis. This may be a confounding factor in the results and thus the conclusions. However, outcomes that could not be entirely pooled owing to skewness of the data and lack of report of mean and standard deviation in some studies (change in SaO 2 , change in clinical score, and change in PEFR), were not significantly different between the two spacer devices in these studies.
In summary, this review has demonstrated that all of the analyzed outcomes were not significantly different when home-made spacers were compared with commercial devices in delivering bronchodilator therapy to children with acute exacerbations of wheezing or asthma. However, further studies are needed in order to support or to refute the use of home-made spacers in delivering bronchodilator therapy to these children. These additional studies should include assessment of clinically important outcomes such as rate of hospitalization or rate of ICU admission, and should be designed and adequately powered to test equivalence (null hypothesis that one device is superior to the other), and also should be designed to compare the two spacers, using lower doses of bronchodilators. Additionally, cost-effectivity analysis and patient preferences are important considerations that require still further assessment, and must be considered in these additional studies.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Overall, this review did not identify a difference between these two delivery methods for delivering bronchodilator therapy to children with acute asthma or lower airways obstruction attacks. However, because of the small number of RCTs along with few events available meeting the criteria for inclusion in the review, absence of the primary outcome of interest and other clinically important outcomes in the majority of included studies, we consider that the results of this review should be interpreted with caution and need confirmation through further, larger trials. In the meanwhile, selection of the spacer device for an individual patient should begin with a commercial spacer with home-made spacers being used if commercial device is not available. The possible need for a facemask in younger children using home-made spacers should be considered.
Implications for research
Further studies are needed before we can confidently draw conclusions about the efficacy of home-made spacers in delivering bronchodilator therapy to children with acute exacerbations of wheezing or asthma. These additional studies should include assessment of clinically important outcomes such as rate of hospitalization or rate of ICU admission, and should be designed and adequately powered to test equivalence (null hypothesis that one device is superior to the other), in order to evaluate whether the theoretical advantages of commercial spacers over non-valved devices (including home-made devices) are so important as to influence the bronchodilator response in evaluating clinically important outcomes. The use of a mask with home-made spacers in small children also needs further clarification. Additionally, cost-effectiveness and patient preferences are important considerations that require further assessment, and should be considered in these additional studies.
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T A B L E S
Characteristics of included studies
Study Chong Neto 2005
Methods Design: Randomized, placebo-controlled study (four arms). Randomisation: Children were asked to draw a slip of paper that determined which group they were in. Blinding: double-blind. Excluded: described. Withdrawals: none. Baseline characteristics: comparable. Power calculation: calculation of sample size necessary to establish significant differences (P < 0.05) between groups for a 15% increase in FEV1 with a power of 80%. Modified Jadad score: 4 Participants Setting: Emergency health unit affiliated with the City Hall of Curitiba. 40 children (10 in each arm) aged 6 to 18 years (average age 11.01 years). Inclusion criteria: patients with acute asthma attacks who sought medical care. Exclusion criteria: history of cardiac and pulmonary diseases other than asthma, clinical score < 3, FEV1 < 20% and greater than 80% of the predicted value, smokers, children treated with short-acting and long-acting beta-2 agonists in the last 24 hours, corticosteroids in the last 7 days, and those receiving xanthines. Interventions Beta-agonist: salbutamol (albuterol). Home-made spacer: sealed 500 ml mineral water bottle. Dosage: 4 puffs (400 µg) given every 20 minutes during one hour (total dosage: 1200). Co-interventions: not stated Beta-agonist: salbutamol (albuterol). Commercial spacer: Aerochamber 145 ml. Dosage: 4 puffs (400 µg) given every 20 minutes during one hour (total dosage: 1200). Co-interventions: not stated.
Outcomes
Primary outcomes: Change in clinical score, FEV1, and heart rate per minute. Secondary outcomes (adverse effects): tremor, nausea and/or vomiting, and hypokalemia.
Notes Allocation concealment A -Adequate
Study Panicker 2001
Methods Design: Parallel group study. Randomisation: computer generated random numbers. Blinding: no details. Excluded: described. Withdrawals: none. Baseline characteristics: comparable. Power calculation: not given. Modified Jadad score: 2 Participants Setting: India. Emergency room department. 60 children (30 in each group) aged 1 to 12 years (average age 4.8 years). Inclusion criteria: over two previous attacks of asthma exacerbation, and children seeking treatment for an acute exacerbation of bronchial asthma. Exclusion criteria: pulmonary tuberculsis, emphysema, other cardiac, hepatic, pulmonary, or skeletal disease involving the spine, any neuromuscular disorder involving intercostal muscle or diaphragm, or children who had already received steroids before going to hospital.
Interventions Beta-agonist: salbutamol (albuterol). Home-made spacer: 750 ml (final volume) plastic water bottle. Dosage: 2 puffs (200 µg) given every 5 -10 minutes during one hour (total dosage: 1200 -2400 µg). Co-interventions: humidified oxygen was given to all patients. Cases with incomplete or poor response at 60 minutes were given further treatment. Beta-agonist: salbutamol (albuterol). Commercial spacer: Cipla 750 ml. Dosage: 2 puffs (200 µg) given every 5 -10 minutes during one hour (total dosage: 1200 -2400 µg). Co-interventions: humidified oxygen was given to all patients. Cases with incomplete or poor response at 60 minutes were given further treatment.
Outcomes
Primary outcomes: Change in grading of dyspnoea, ability to speak, heart rate per minute, respiratory rate, cyanosis, accesory muscle use, breth sounds, rhonchi, PEFR, pulsus paradoxus, arterial blood gas, and oxygen saturation. Notes Allocation concealment B -Unclear Inclusion criteria: children with a known history of asthma who presented to the Hospital with an acute asthma attack. Exclusion criteria: inability to use an MDI and spacer or to reliably undergo pulmonary function tests, PEFR < 20% of the predicted normal, arterial oxygen saturation < 92% in air, underlying cardiac or other chronic chronic pulmonary disease, treatment with oral corticosteroids for more than 5 days before presentation, and use of beta-agonists within 4hours of presentation.
Interventions Beta-agonist: fenoterol hydrobromide. Home-made spacers: sealed 500 ml plastic cold-drink bottle, unsealed 500 ml plastic cold-drink bottle, and 200 ml polystyrene cup. Dosage: 4 puffs (400 µg) for children who weighed 25 kg or less, and 6 puffs (600 µg) for children who weighed more than 25 kg, given at a rate of 1 puff every 10 seconds. Co-interventions: fenoterol 1000 µg in 2 ml normal saline via a jet nebuliser, and oxygen at a flow rate of 5 L per min in children who after bronchodilator treatment had PEFR < 70% of the predicted value. Beta-agonist: fenoterol hydrobromide. Commercial spacer: Aerochamber 145 ml. Dosage: 4 puffs (400 µg) for children who weighed 25 kg or less, and 6 puffs (600 µg) for children who weighed more than 25 kg, given at a rate of 1 puff every 10 seconds. Co-interventions: fenoterol 1000 µg in 2 ml normal saline via a jet nebuliser, and oxygen at a flow rate of 5 L per min in children who after bronchodilator treatment had PEFR < 70% of the predicted value. 
Characteristics of excluded studies (Continued )
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